NASDAQ:GRTX Galera Therapeutics (GRTX) Stock Price, News & Analysis $0.02 +0.00 (+8.11%) As of 03:09 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsTrendsBuy This Stock About Galera Therapeutics Stock (NASDAQ:GRTX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Galera Therapeutics alerts:Sign Up Key Stats Today's Range$0.02▼$0.0250-Day Range$0.02▼$0.0452-Week Range$0.02▼$0.23Volume37,022 shsAverage Volume117,216 shsMarket Capitalization$1.81 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewGalera Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule dismutase mimetic for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC); for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; and for patients with HNC undergoing standard-of-care radiotherapy. It also develops rucosopasem manganese (rucosopasem) to augment the anti-cancer efficacy of stereotactic body radiation therapy in patients with non-small cell lung cancer and locally advanced pancreatic cancer. The company was incorporated in 2012 and is based in Malvern, Pennsylvania.Read More… Receive GRTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Galera Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address GRTX Stock News HeadlinesGalera Therapeutics extends agreement deadlineApril 4, 2025 | investing.comSt. Louis-born Galera Therapeutics sidesteps liquidation, acquires New York biotech companyJanuary 2, 2025 | bizjournals.comElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of collapse and built two of the most valuable companies in history. Now, he's sounding the alarm about America's $36 trillion debt time bomb that could destroy the fabric of our society.As head of the Department of Government Efficiency (DOGE) under President Trump, Musk is exposing just how bad things are...May 2, 2025 | American Hartford Gold (Ad)Galera Therapeutics completes acquisition of Nova PharmaceuticalsDecember 31, 2024 | globenewswire.comGalera Therapeutics (OTC:GRTX) Stock, Short Interest ReportOctober 6, 2024 | benzinga.comGalera Therapeutics (OTC:GRTX) Stock Quotes, Forecast and News SummaryOctober 6, 2024 | benzinga.comNewron Pharmaceuticals S.p.A. (NP5.DE)August 18, 2024 | finance.yahoo.comGRTX Galera Therapeutics, Inc.August 16, 2024 | seekingalpha.comSee More Headlines GRTX Stock Analysis - Frequently Asked Questions How have GRTX shares performed this year? Galera Therapeutics' stock was trading at $0.0458 at the start of the year. Since then, GRTX stock has decreased by 51.5% and is now trading at $0.0222. View the best growth stocks for 2025 here. How were Galera Therapeutics' earnings last quarter? Galera Therapeutics, Inc. (NASDAQ:GRTX) posted its quarterly earnings results on Wednesday, November, 10th. The company reported ($0.86) EPS for the quarter, missing analysts' consensus estimates of ($0.71) by $0.15. When did Galera Therapeutics IPO? Galera Therapeutics (GRTX) raised $75 million in an initial public offering on Thursday, November 7th 2019. The company issued 5,000,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Citigroup and Credit Suisse served as the underwriters for the IPO and BTIG was co-manager. How do I buy shares of Galera Therapeutics? Shares of GRTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Galera Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Galera Therapeutics investors own include Energy Transfer (ET), Plug Power (PLUG), NGL Energy Partners (NGL), Universal Display (OLED), Nextera Energy Partners (NEP), Verastem (VSTM) and Alerian MLP ETF (AMLP). Company Calendar Last Earnings11/10/2021Today5/02/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:GRTX CIK1563577 Webwww.galeratx.com Phone610-725-1500FaxN/AEmployees30Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.35) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-59,080,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-99.34% Debt Debt-to-Equity RatioN/A Current Ratio9.74 Quick Ratio9.74 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($2.41) per share Price / Book-0.01Miscellaneous Outstanding Shares75,462,000Free Float47,375,000Market Cap$1.81 million OptionableOptionable Beta1.94 5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (NASDAQ:GRTX) was last updated on 5/2/2025 by MarketBeat.com Staff From Our PartnersWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredMusk's warning signal: Prepare before the cascade beginsWhen Elon Musk triggered his AI layoff plan, most analysts missed what it really meant. Louis Navellier didn’t...InvestorPlace | SponsoredElon Musk is all in on these robots …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Galera Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Galera Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.